Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron
Melanie Schürz(University of Salzburg), Nicole Meisner‐Kober(Novartis (Switzerland)), Sandra Laner‐Plamberger(Paracelsus Medical University), N. Mayr(University of Salzburg), Hans Brandstetter(University of Salzburg), Martin Hintersteiner, Katharina Schallmoser(Medical University of Graz), Martin Wolf(Paracelsus Medical University), Eva Klinglmayr(University of Salzburg), Heloisa Melo Benirschke(University of Salzburg), Arianna Venturini(Telethon Institute Of Genetics And Medicine), Nicoletta Pedemonte(Istituto Giannina Gaslini), Luis J. V. Galietta(Federico II University Hospital), Martin Mayora Neto(Medway School of Pharmacy), Elisa Vicenzi(Mario Negri Institute for Pharmacological Research), Isabel Pagani(Vita-Salute San Raffaele University), E. Emminger(Paracelsus Medical University), Nigel Temperton(Medway School of Pharmacy), Valeria Capurro(Istituto Giannina Gaslini), Liliia Paniushkina(Paracelsus Medical University), Dirk Strunk(Paracelsus Medical University), Cyrus Kohlmetz(University of Salzburg), Christoph Grabmer(Paracelsus Medical University)
Cited by 4
Related Papers
SARS-CoV-2 evolution during treatment of chronic infection
|Nature|2021|1.1k
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity
|Nature Medicine|2011|544
T Cell Responses to Whole SARS Coronavirus in Humans
|The Journal of Immunology|2008|541